This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.
Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.
Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.
Why the Earnings Surprise Streak Could Continue for Hologic (HOLX)
by Zacks Equity Research
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.
New Strong Buy Stocks for July 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
HOLX vs. TCMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. TCMD: Which Stock Is the Better Value Option?
Women Health a Top Priority Now: 3 Stocks to Watch
by Sreyoshi Mukherjee
Women's healthcare gains global importance, investors might want to keep an eye on these stocks.
5 Best GARP Stocks With Discounted PEG
by Urmimala Biswas
A lower PEG ratio, preferably less than 1, is always better for GARP investors.
Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Hologic (HOLX) is generating consistent positive results, courtesy of growth initiatives.
Hologic (HOLX) Inks Deal to Acquire SuperSonic Imagine
by Zacks Equity Research
The acquisition of SuperSonic Imagine is in sync with Hologic's (HOLX) strategy to provide wide-ranging screening, interventional and surgical solutions.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Hologic (HOLX) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
by Zacks Equity Research
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.
Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.
Hologic (HOLX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's Diagnostics Grows Strong, Escalating Costs a Woe
by Zacks Equity Research
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
by Zacks Equity Research
ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.
Genomic Health's New Positive Data to Boost Test Uptake
by Zacks Equity Research
Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.
QIAGEN Unveils Liquid Biopsy Workflows & Panels, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.